These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483 [TBL] [Abstract][Full Text] [Related]
46. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target. Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351 [TBL] [Abstract][Full Text] [Related]
47. Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence. Schick U; Kyula J; Barker H; Patel R; Zaidi S; Gregory C; Hafsi H; Roulstone V; Deutsch E; McLaughlin M; Harrington K Radiother Oncol; 2015 Nov; 117(2):364-75. PubMed ID: 26163092 [TBL] [Abstract][Full Text] [Related]
48. Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer. Jeanson A; Boyer A; Greillier L; Tomasini P; Barlesi F Expert Rev Anticancer Ther; 2019 Jan; 19(1):11-17. PubMed ID: 30513023 [No Abstract] [Full Text] [Related]
49. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors. Hashida S; Yamamoto H; Shien K; Ohtsuka T; Suzawa K; Maki Y; Furukawa M; Soh J; Asano H; Tsukuda K; Miyoshi S; Kanazawa S; Toyooka S Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753 [TBL] [Abstract][Full Text] [Related]
50. MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer. de Leeuw R; McNair C; Schiewer MJ; Neupane NP; Brand LJ; Augello MA; Li Z; Cheng LC; Yoshida A; Courtney SM; Hazard ES; Hardiman G; Hussain MH; Diehl JA; Drake JM; Kelly WK; Knudsen KE Clin Cancer Res; 2018 Sep; 24(17):4201-4214. PubMed ID: 29739788 [No Abstract] [Full Text] [Related]
52. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303 [TBL] [Abstract][Full Text] [Related]
53. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs. Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298 [TBL] [Abstract][Full Text] [Related]
54. "RB-reactivator screening" as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist). Sakai T Pharmacol Ther; 2022 Aug; 236():108234. PubMed ID: 35732246 [TBL] [Abstract][Full Text] [Related]
55. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC. Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725 [TBL] [Abstract][Full Text] [Related]
56. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Shapiro GI; Park JE; Edwards CD; Mao L; Merlo A; Sidransky D; Ewen ME; Rollins BJ Cancer Res; 1995 Dec; 55(24):6200-9. PubMed ID: 8521414 [TBL] [Abstract][Full Text] [Related]
57. Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer. Toulany M; Iida M; Keinath S; Iyi FF; Mueck K; Fehrenbacher B; Mansour WY; Schaller M; Wheeler DL; Rodemann HP Oncotarget; 2016 Jul; 7(28):43746-43761. PubMed ID: 27248324 [TBL] [Abstract][Full Text] [Related]
58. Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects. Li B; Torossian A; Sun Y; Du R; Dicker AP; Lu B Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e525-31. PubMed ID: 22836051 [TBL] [Abstract][Full Text] [Related]